Ionis Pharmaceuticals (IONS) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue grew 10% year-over-year to $132 million, driven by TRYNGOLZA's first independent commercial launch and increased royalties from SPINRAZA and WAINUA.

• TRYNGOLZA generated over $6 million in net sales in its first full quarter, exceeding expectations with strong patient uptake and favorable payer coverage.

• 2025 financial guidance was raised by more than 20% across all metrics, reflecting strong Q1 results, successful licensing transactions, and pipeline progress.

• Multiple late-stage pipeline assets, including donidalorsen, olezarsen, and zilganersen, are advancing toward regulatory milestones and launches over the next three years.

• Strong liquidity with $2.1 billion in cash and investments supports ongoing commercialization and pipeline advancement.

Financial highlights

• Q1 2025 revenue reached $132 million, up from $119 million in Q1 2024; commercial revenue rose 28% year-over-year, with $76 million from commercial products.

• SPINRAZA royalties were $48 million (+25% YoY); WAINUA royalties reached $9 million.

• Non-GAAP operating expenses were $249 million, with R&D expenses down and SG&A up to support launches.

• Licensing of Sapablursen generated $280 million, contributing to increased revenue guidance.

• Net loss for Q1 2025 was $146.9 million (GAAP), with non-GAAP net loss at $118 million, both improved from Q1 2024.

Outlook and guidance

• 2025 revenue guidance raised to $725–$750 million (previously >$600 million), with non-GAAP operating loss guidance improved to less than $375 million.

• Year-end cash guidance increased to ~$1.9 billion, with anticipated positive cash flow as product and royalty revenues grow.

• Multiple product launches expected, including donidalorsen for HAE (Q3 2025) and potential launches for olezarsen and zilganersen pending phase III data.

• Full-year 2025 operating expenses projected to rise in the high-single-digit percentage range, mainly due to SG&A for launches.

• Peak annual product sales from owned medicines expected to exceed $3 billion, with partnered medicines contributing over $2 billion in peak royalties.